SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-021955
Filing Date
2022-08-11
Accepted
2022-08-11 06:25:49
Documents
73
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 889735
2 ex31-1.htm EX-31.1 11376
3 ex31-2.htm EX-31.2 11581
4 ex32-1.htm EX-32.1 8067
5 form10-q_001.jpg GRAPHIC 5509
  Complete submission text file 0001493152-22-021955.txt   4490826

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE mtnb-20220630.xsd EX-101.SCH 39070
7 XBRL CALCULATION FILE mtnb-20220630_cal.xml EX-101.CAL 54499
8 XBRL DEFINITION FILE mtnb-20220630_def.xml EX-101.DEF 116686
9 XBRL LABEL FILE mtnb-20220630_lab.xml EX-101.LAB 304017
10 XBRL PRESENTATION FILE mtnb-20220630_pre.xml EX-101.PRE 242007
67 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 626348
Mailing Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921
Business Address 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER NJ 07921 908-484-8805
Matinas BioPharma Holdings, Inc. (Filer) CIK: 0001582554 (see all company filings)

IRS No.: 463011414 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38022 | Film No.: 221153546
SIC: 2834 Pharmaceutical Preparations